Evidence map›Paper›PMID 30788835›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2019

The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study.

I Manzanedo, F Pereira, Á Serrano, E Pérez-Viejo, B Martínez-Torres, L Carrión, J Calzas

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

I ManzanedoPeritoneal Carcinomatosis Unit, Department of General and Digestive Surgery, University Hospital of Fuenlabrada, C/ Camino del Molino 2, 28942, Fuenlabrada, Madrid, Spain. israel.manzanedo@salud.madrid.org.ORCID http://orcid.org/0000-0003-4188-1740
F PereiraPeritoneal Carcinomatosis Unit, Department of General and Digestive Surgery, University Hospital of Fuenlabrada, C/ Camino del Molino 2, 28942, Fuenlabrada, Madrid, Spain.
Á SerranoPeritoneal Carcinomatosis Unit, Department of General and Digestive Surgery, University Hospital of Fuenlabrada, C/ Camino del Molino 2, 28942, Fuenlabrada, Madrid, Spain.
E Pérez-ViejoPeritoneal Carcinomatosis Unit, Department of General and Digestive Surgery, University Hospital of Fuenlabrada, C/ Camino del Molino 2, 28942, Fuenlabrada, Madrid, Spain.
B Martínez-TorresDepartment of General and Digestive Surgery, University Hospital of Fuenlabrada, C/Camino del Molino 2, 28942, Fuenlabrada, Madrid, Spain.
L CarriónDepartment of General and Digestive Surgery, University Hospital of Fuenlabrada, C/Camino del Molino 2, 28942, Fuenlabrada, Madrid, Spain.
J CalzasDepartment of Medical Oncology, University Hospital of Fuenlabrada, C/Camino del Molino 2, 28942, Fuenlabrada, Madrid, Spain.
Universidad Rey Juan Carlos · ESHospital Universitario de Fuenlabrada · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOur main aim is to analyze the survival results in women operated on for advanced ovarian cancer with two different HIPEC regimens (cisplatin plus doxorubicin versus paclitaxel). PATIENTS AND

methodsA prospective cohort of patients with stage IIIC or IV epithelial ovarian cancer operated on with cytoreductive surgery and HIPEC, from October-2008 to February-2016, was retrospectively analyzed. The two drugs used, cisplatin/doxorubicin (Group A) and paclitaxel (Group B), were compared.

resultsForty-one patients were treated with cytoreductive surgery and HIPEC; 19 patients (46%) were in Group A and 22 (54%) were in Group B. The extent of peritoneal disease was comparable between groups (Peritoneal Cancer Index of 10 in Group A versus PCI of 12.5 in Group B). There were no differences in morbidity between groups, with a severe morbidity (Dindo-Clavien III or IV) of 36.8% versus 27.3%, respectively. There was no postoperative mortality. Median follow-up was 39 months. Median overall survival was 79 months. Overall survival at 3 years in Group A was 66% versus 82.9% in Group B (p = 0.248). Incomplete cytoreduction (macroscopic residual tumour after surgery) was identified as the only independent factor that influenced overall survival (HR 12.30, 95% CI 1.28-118.33, p = 0.03). The cytostatic used in HIPEC had no influence in overall survival.

conclusionThe cytostatic used in HIPEC did not have a negative effect in the prognosis of patients with advanced ovarian cancer.

Indexed as

Hyperthermia, InducedAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Ovarian EpithelialCisplatinCombined Modality TherapyCytoreduction Surgical ProceduresDoxorubicinFemaleHumansMiddle AgedNeoplasm, ResidualOvarian NeoplasmsPaclitaxelPeritoneal NeoplasmsCisplatinDoxorubicinPaclitaxelChemotherapyCytostatic agentsHIPECOvarian cancerPeritoneal carcinomatosis

Identifiers

PMID30788835
OpenAlexW2915710615

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.